TheraRadar
Landscape / Oncology
Page updated Jul 4, 2026 · using data updated on Jun 28, 2026

Multiple Myeloma Clinical Trial Landscape

Multiple myeloma is a cancer that forms in plasma cells, a type of white blood cell. These cancerous cells accumulate in the bone marrow and crowd out healthy blood cells.

The clinical trial landscape for multiple myeloma is robust, with 1,892 trials registered since 2008, including 670 currently active trials. Activity is heavily concentrated in early-to-mid stage development, with 271 active Phase 1 trials and 398 active Phase 2 trials, compared to 110 active Phase 3 trials and 18 active Phase 4 trials.

Johnson & Johnson leads industry sponsorship of active trials with 29, followed by GSK with 18, AbbVie with 16, Regeneron with 11, and Bristol-Myers Squibb with 10. The high volume of Phase 1 and 2 trials suggests a strong focus on novel therapeutic approaches and dose optimization in this indication.

Trial activity

678 active / 1,923 total since 2008
Active by phase 113 Ph3 / 231 389 Ph2 / 1101 159 Ph1 / 555 17 Ph4 / 36

Competitive Intelligence

This Multiple Myeloma competitive landscape maps 13 companies against 15 mechanisms of action (MOA) across 24 active drug-development programs, including 2 with a confirmed FDA PDUFA date. Each cell is the lead program for a company–mechanism pair — its trial phase, modality, combination, and nearest readout. Read down a column to see who is competing on the same mechanism in Multiple Myeloma, across a row to see one company's mechanistic spread, and click any cell for the full program list and trial links.

Beta 13 companies 15 mechanisms 24 programs mapped 7 lowTrust (29%) 2 ⚖ PDUFA-dated ⏰ 8 due ≤6 mo click any cell → asset tearsheet
At a glance

Multiple Myeloma shows 24 programs across 13 companies and 15 mechanisms. The most contested mechanism is CD3 (11 programs).

Key findings
  • 58% of CD3 programs (7 of 12) are combos with novel agents — class-extension work, not class-validation.
  • Top 3 mechanisms (CD3, Anti-CD38 (mAb), BCMA) account for ~35% of programs — class concentration is low.
  • Johnson & Johnson runs 15 programs — the deepest pipeline in this view.
  • Bristol-Myers Squibb has the highest composite score (100) — most-imminent / most-advanced asset weighted higher than program count.
  • 17 hot readouts in next 6 months — most imminent: iCell Gene (BCMA+CD19).
  • 22 trials are stale (overdue without status change) — possible class-maturity inflection or operational issue.
  • 15 single-program mechanisms in the long tail — 7 are Ph2+ first-in-class first-mover bets.
  • 5 NME candidates in the long tail.
  • Most-novel-of-novel: Guangzhou Gloria CXCR4 (Ph3) — first-in-class within scope + NME candidate.

Forward catalysts next 18 months⏰ 8 due ≤6 mo⚖ 2 PDUFA-dated

Nearest first. ⚖ Confirmed FDA PDUFA dates (curated calendar, primary sources) and 📅 estimated readouts (ClinicalTrials.gov primaryCompletionDate — a timing proxy, not a confirmed action date). Red = due within 6 months.

Company × Mechanism

Each cell = a company’s most-advanced program in that mechanism. Click for the asset tearsheet.
Unverified (lowTrust) cells:
Ph1 Ph2 Ph3 Ph4 ⚠ lowTrust +combo
Select & Focus Pro → 🔒 Transpose, filtering, selection & export are Pro (search & sort are free) — start a free trial, or try them free on our showcase →
CD3
T cell surface glycoprotein CD3
Anti-CD38 (mAb)
BCMA
BCMA × CD3 (bispecific)
FCGRH3
CEREBLON
BCMA/CD19
BCMA CAR-T (autoimmune)
GPRC5D
CRL4(CRBN) E3 ubiquitin ligase in…
26S PROTEASOME
BCMA/GPRC5D T-cell engager
BCMA × CD3 bispecific
Lymphocyte differentiation antige…
Johnson & Johnson
Regeneron
Bristol-Myers Squibb
GSK
AbbVie
Roche / Genentech
AstraZeneca
Sanofi
Kite, A Gilead Company
🇨🇳Qilu
Chongqing Precision
Keymed
Oncotherapeutics

Phase 3 leaders · most advanced

  1. active AbbVie NCT03844048
  2. recruiting Juno Therapeutics, Inc., a Bristol-Myers Squibb Company NCT06615479
  3. recruiting AbbVie NCT07095452
  4. recruiting Shandong New Time Pharmaceutical Co., LTD NCT07579234
  5. recruiting Canadian Cancer Trials Group NCT06182774

Beyond the grid Beta

What the matrix leaves out — rare mechanisms with only one player, small & emerging sponsors, and programs we haven’t classified yet.

Single-company mechanisms — BD white space 9 found

Mechanisms only ONE company is pursuing in this indication — the uncrowded / first-in-class bets the matrix cap hides. ⚡ first-in-class · ⚠ unverified mechanism. ⚡ first-in-class is computed across 61 mapped landscapes — scope-limited, not a global claim.
⚡ first-in-class · 🌱 first-in-indication · 🆕 NME candidate · ✅ AI-classified + verified · ⚙️ AI-classified, unverified · first-in-class computed across 61 mapped landscapes
Single-program mechanisms (15) — one program each — earliest-stage, sorted by phase
PhaseMechanismCompanyModalityReadoutTrial
Ph3 26S proteasome inhibitor ⚡ 🌱 Bristol-Myers Squibb ⏰ 3Q26 NCT05552976
Ph3 CXCR4 ⚡ 🌱 🆕 Guangzhou Gloria Cell therapy ⏰ 4Q26 NCT06514508
Ph3 IMMUNOGLOBULIN ⚡ 🌱 Grifols Biologicals 3Q28 NCT07582432
Ph2 20S PROTEASOME ⚡ 🌱 Sanofi SC ⏰ 1Q27 NCT06356571
Ph2 BCL-2 🌱 Oncotherapeutics Oral ⏰ 2Q26 NCT06115135
Ph1+Ph2 Gamma-secretase inhibitor ⚡ 🌱 GSK 2Q25 NCT07084896
Ph1+Ph2 GPRC5D ADC ⚡ 🌱 AstraZeneca SC 3Q27 NCT06106945
Ph1+Ph2 HDAC 🌱 🆕 Chengdu Zenitar Biomedica… 1Q26 NCT06484829
Ph1+Ph2 MENIN 🌱 Sumitomo Pharma America Oral 2Q27 NCT04988555
Ph2 SARS-COV-2 ⚡ 🌱 GeoVax ⏰ 4Q26 NCT04977024
Ph1 BCMA+CD19 🌱 🆕 iCell Gene ⏰ 3Q26 NCT04162353
Ph1 FLT3 🌱 🆕 Senti Cell therapy 1Q26 NCT06325748
Ph1 MICA/MICB ⚡ 🌱 🆕 Cullinan ⏰ 3Q26 NCT06381141
Ph1 PD-1 inhibitor 🌱 Johnson & Johnson SC 2Q25 NCT05338775
Ph1 Proteasome inhibitor ⚡ 🌱 K36 4Q27 NCT05651932
Emerging & small-cap sponsors (20) — few programs here — partnering / M&A radar
PhaseMechanismCompanyModalityReadoutTrial
Ph3 Lymphocyte differentiation antigen CD38 inhibitor ⚡ Biocad 1Q25 NCT06296121
Ph1 T cell surface glycoprotein CD3 C4 SC 4Q28 NCT07280013
Ph1 BCMA ⚡ Caribou Cell therapy 4Q27 NCT05722418
Ph1+Ph2 GPRC5D ⚡ CARsgen Cell therapy 2Q27 NCT06333509
Ph2 CRL4(CRBN) E3 ubiquitin ligase inhibitor ⚡ CellCentric 4Q29 NCT07096778
Ph3 Anti-CD38 (mAb) Celltrion SC 4Q27 NCT06952478
Ph2 🇨🇳 BCMA × CD3 bispecific Genrix (Shanghai) Biophar… 2Q27 NCT06566547
Ph2 BCMA ⚡ Hrain Cell therapy 3Q25 NCT05594797
Ph1+Ph2 XPO1 ⚡ Karyopharm 2Q27 NCT02343042
Ph1 🇨🇳 GPRC5D ⚡ Nanjing IASO 3Q25 NCT05759793
Ph1 BCMA ⚡ O&D 1Q28 NCT07369895
Ph3 CD3 Pfizer SC ⏰ 3Q26 NCT06152575
Ph1 BCMA ⚡ Poseida Cell therapy 1Q29 NCT04960579
Ph2 🇨🇳 Anti-CD38 (mAb) Shandong New Time 2Q28 NCT07312188
Ph1+Ph2 🇨🇳 BCMA ⚡ Shanghai AbelZeta 3Q24 NCT05521802
Ph1 🇨🇳 Anti-CD38 (mAb) Shanghai Henlius 2Q27 NCT07477587
Ph1+Ph2 Anti-CD38 (mAb) Sorrento 4Q25 NCT05308225
Ph1+Ph2 CRL4(CRBN) E3 ubiquitin ligase inhibitor ⚡ Starton SC ⏰ 2Q26 NCT06087653
Ph2 XPO1 ⚡ US Oncology Research Oral ⏰ 2Q26 NCT04782687
Ph1+Ph2 🇨🇳 Anti-CD38 (mAb) Zhejiang ACEA ⏰ 4Q26 NCT05565807
Unclassified programs (119) — mechanism not captured yet
PhaseMechanismCompanyModalityReadoutTrial
Ph3 BMS-986393, Cyclophosphamide, Fludarabineunclassified Juno Therapeutics, Inc., … NCT06615479
Ph2+Ph3 Etentamig, Lenalidomide, Daratumumabunclassified AbbVie NCT07095452
Ph3 F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone…unclassified Shandong New Time Pharmac… NCT07579234
Ph3 Daratumumab, Pomalidomide, Dexamethasoneunclassified Janssen Research & Develo… NCT05083169
Ph3 Bortezomib, Dexamethasone, Lenalidomideunclassified Janssen Research & Develo… NCT04923893
Ph3 Linvoseltamab, Carfilzomib, Daratumumabunclassified Regeneron Pharmaceuticals NCT07222761
Ph3 Teclistamab, Daratumumab, Lenalidomideunclassified Janssen Research & Develo… NCT05552222
Ph3 TQB2934 injection, Pomalidomide Capsule, Selinexor tabletsunclassified Chia Tai Tianqing Pharmac… NCT07569757
Ph3 Elranatamab, Daratumumab, Lenalidomideunclassified Pfizer NCT05623020
Ph3 Elranatamab, Daratumumab, Pomalidomideunclassified Pfizer NCT05020236
Ph3 Isatuximab SAR650984, Bortezomib, Lenalidomideunclassified Sanofi NCT03319667
Ph3 mezigdomide, Pomalidomide, Bortezomibunclassified Celgene NCT05519085
Ph3 Cevostamab, Pomalidomide, Dexamethasoneunclassified Hoffmann-La Roche NCT07555938
Ph3 Belantamab mafodotin, Lenalidomide, Dexamethasoneunclassified GlaxoSmithKline NCT06679101
Ph3 Elranatamab, Lenalidomide, Lenalidomideunclassified Pfizer NCT05317416
Ph3 Xembify, Placebounclassified Grifols Therapeutics LLC NCT05645107
Ph3 Talquetamab, Daratumumab, Pomalidomideunclassified Janssen Research & Develo… NCT05455320
Ph3 Teclistamab, Pomalidomide, Bortezomibunclassified Janssen Research & Develo… NCT05572515
Ph3 IGI, 10%unclassified Takeda NCT06980480
Ph3 Dexamethasone, Daratumumab, Bortezomibunclassified Celgene NCT04975997
Ph3 GR1803 injection, Daratumumab, Pomalidomideunclassified Genrix (Shanghai) Biophar… NCT07452198
Ph3 Linvoseltamab, Daratumumabunclassified Regeneron Pharmaceuticals NCT07393282
Ph3 Etentamig, Carfilzomib, Pomalidomideunclassified AbbVie NCT06158841
Ph3 Talquetamab, Pomalidomide, Teclistamabunclassified Janssen Research & Develo… NCT06208150
Ph3 Linvoseltamab, Elotuzumab, Pomalidomideunclassified Regeneron Pharmaceuticals NCT05730036
Ph3 QLS32015, Pomalidomide, Selinexorunclassified Qilu Pharmaceutical Co., … NCT07138209
Ph3 SCTC21C, Bortezomib, Lenalidomideunclassified Sinocelltech Ltd. NCT07297329
Ph3 Isatuximab IV, Isatuximab SC, Dexamethasoneunclassified Sanofi NCT05405166
Ph3 Equecabtagene Autoleucel Injection, Daratumumab, Pomalidomideunclassified Nanjing IASO Biotechnolog… NCT06464991
Ph3 SG301 Injection, SG301 placebo, pomalidomideunclassified Hangzhou Sumgen Biotech C… NCT06508983
Ph3 Pomalidomide, Dexamethasone, Venetoclaxunclassified AbbVie NCT03539744
Ph3 HLX15-IV, Darzalexunclassified Shanghai Henlius Biotech NCT06895512
Ph3 A Study of Evaluating the Safety and Efficacy of ATG-010, Borte…unclassified Antengene Corporation NCT04939142
Ph3 QL2109, Pomalidomide, Dexamethasoneunclassified Qilu Pharmaceutical Co., … NCT06742138
Ph3 Pomalidomide Capsules, Bortezomib for Injection, Daratumumab In…unclassified Innovent Biologics (Suzho… NCT07623798
Ph3 IgPro20unclassified CSL Behring NCT07648264
Ph3 Ramantamig, Daratumumab, Lenalidomideunclassified Janssen Research & Develo… NCT07665450
Ph1+Ph2 Sonrotoclax, Dexamethasone, Carfilzomibunclassified BeOne Medicines NCT04973605
Ph1+Ph2 mRNA-2808unclassified ModernaTX, Inc. NCT07116616
Ph2 Talquetamab, Prophylaxis A, Prophylaxis Bunclassified Janssen Research & Develo… NCT06500884
Ph2 JNJ-79635322unclassified Janssen Research & Develo… NCT07266441
Ph2 Cilta-cel, Talquetamab, Daratumumabunclassified Janssen Research & Develo… NCT06577025
Ph1+Ph2 Belantamab mafodotin, GSK3174998, Feladilimabunclassified GlaxoSmithKline NCT04126200
Ph1+Ph2 Cevostamab, Lenalidomide, Tocilizumabunclassified Hoffmann-La Roche NCT05583617
Ph2 Belantamab mafodotin, Dexamethasone, Pomalidomideunclassified GlaxoSmithKline NCT07227311
Ph1+Ph2 Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell In…unclassified Nanjing IASO Biotechnolog… NCT07510100
Ph2 Cemsidomide, Dexamethasoneunclassified C4 Therapeutics, Inc. NCT07284758
Ph1+Ph2 SG2918unclassified Hangzhou Sumgen Biotech C… NCT07454187
Ph1+Ph2 GC012Funclassified Gracell Biotechnologies (… NCT06235229
Ph1+Ph2 IBI3003unclassified Fortvita Biologics (USA)I… NCT07336472
Ph1+Ph2 ABBV-453, Daratumumab, Dexamethasoneunclassified AbbVie NCT06953960
Ph1+Ph2 Autologous BCMA-targeting CAR T cellsunclassified Hebei Senlang Biotechnolo… NCT07421856
Ph1+Ph2 Etentamig, Lenalidomide, Dexamethasoneunclassified AbbVie NCT06892522
Ph1+Ph2 TNB-383Bunclassified AbbVie NCT03933735
Ph2 Selinexor, Dexamethasone, Bortezomibunclassified Karyopharm Therapeutics I… NCT04414475
Ph2 Isatuximab, Carfilzomib, Dexamethasoneunclassified Sanofi NCT05704049
Ph1+Ph2 CCS1477, Pomalidomide, Dexamethasoneunclassified CellCentric Ltd. NCT04068597
Ph1+Ph2 LBL-034 for Injectionunclassified Nanjing Leads Biolabs Co.… NCT06049290
Ph1+Ph2 Belantamab mafodotin, Feladilimabunclassified GlaxoSmithKline NCT07217119
Ph1+Ph2 HuL001-10 mg/kg, HuL001-15 mg/kg, Lenalidomide and Dexamethasoneunclassified HuniLife Biotechnology, I… NCT07210047
Ph2 QLS32015, Pomalidomide, Dexamethasoneunclassified Qilu Pharmaceutical Co., … NCT07018050
Ph1+Ph2 BT02unclassified Biotroy Therapeutics NCT07107204
Ph1+Ph2 CC-92480, Tazemetostat, BMS-986158unclassified Bristol-Myers Squibb NCT05372354
Ph1+Ph2 Belantamab mafodotin, Nirogacestat, Pomalidomideunclassified GlaxoSmithKline NCT07150104
Ph1+Ph2 Belantamab mafodotin, Nirogacestat, Lenalidomideunclassified GlaxoSmithKline NCT07150091
Ph1+Ph2 ODX (Osteodex)unclassified DexTech Medical AB NCT06616389
Ph2 Dexamethasone, Daratumumab, Venetoclaxunclassified AbbVie NCT03314181
Ph2 AUTO CAR T cell therapyunclassified Autolus Limited NCT03628612
Ph2 Carfilzomib, Venetoclax, Dexamethasoneunclassified AbbVie NCT02899052
Ph1+Ph2 GR1803 injection, Anti-CD38 Monoclonal Antibodyunclassified Genrix (Shanghai) Biophar… NCT07090954
Ph1+Ph2 IDP-023, Rituximab, Daratumumabunclassified Indapta Therapeutics, INC. NCT06119685
Ph1+Ph2 OPC-415unclassified Otsuka Pharmaceutical Co.… NCT04649073
Ph1+Ph2 IDP-121unclassified IDP Discovery Pharma S.L. NCT05908409
Ph2 BCD-248unclassified Biocad NCT06668792
Ph1+Ph2 IBI3003unclassified Innovent Biologics (Suzho… NCT06083207
Ph1+Ph2 CC-92480, Bortezomib, Dexamethasoneunclassified Celgene NCT03989414
Ph1+Ph2 HDP-101unclassified Heidelberg Pharma AG NCT04879043
Ph1+Ph2 OriCAR-017unclassified OriCell Therapeutics Co.,… NCT06182696
Ph1+Ph2 MBS314 Injectionunclassified Beijing Mabworks Biotech … NCT06232096
Ph1+Ph2 zevor-celunclassified CARsgen Therapeutics Co.,… NCT03915184
Ph1+Ph2 SYHX1903unclassified CSPC ZhongQi Pharmaceutic… NCT05055791
Ph1 ABBV-438unclassified AbbVie NCT07409246
Ph1 RO7851624unclassified Genentech, Inc. NCT07558915
Ph1 JNJ-79635322unclassified Janssen Research & Develo… NCT05652335
Ph1 JNJ-87562761unclassified Janssen Research & Develo… NCT06604715
Ph1 JNJ-79635322, Daratumumab, Pomalidomideunclassified Janssen Research & Develo… NCT06768489
Ph1 Elranatamab, Iberdomideunclassified Pfizer NCT06215118
Ph1 Cevostamab, Elranatamab, Tocilizumabunclassified Genentech, Inc. NCT05927571
Ph1 KLN-1010unclassified Kelonia Therapeutics, Inc. NCT07075185
Ph1 SHR-9539 for injectionunclassified Suzhou Suncadia Biopharma… NCT06484777
Ph1 HDP-101unclassified Hangzhou Zhongmei Huadong… NCT07529782
Ph1 Elranatamab, Carfilzomib, Maplirpaceptunclassified Pfizer NCT05675449
Ph1 OPN-6602, Dexamethasoneunclassified Opna Bio LLC NCT06433947
Ph1 ISB 2001, ISB 2001unclassified Ichnos Sciences SA NCT05862012
Ph1 cemsidomide, Dexamethasone Oralunclassified C4 Therapeutics, Inc. NCT04756726
Ph1 SAR446523unclassified Sanofi NCT06630806
Ph1 SHR-3836 administered as multiple doses.unclassified Shanghai Hengrui Pharmace… NCT07490613
Ph1 BMS-986453, Fludarabine, Cyclophosphamideunclassified Juno Therapeutics, Inc., … NCT06153251
Ph1 SIM0500unclassified Jiangsu Simcere Pharmaceu… NCT06375044
Ph1 Rimiducid may be administered as indicatedunclassified Poseida Therapeutics, Inc. NCT03741127
Ph1 BMS-986393, Alnuctamab, Mezigdomideunclassified Juno Therapeutics, Inc., … NCT06121843
Ph1 YKST02unclassified Excyte Biopharma Ltd NCT06574568
Ph1 Etentamig, Dexamethasone, Lenalidomideunclassified AbbVie NCT05259839
Ph1 TQB2934 injection (subcutaneous injection)unclassified Chia Tai Tianqing Pharmac… NCT07179679
Ph1 MK-4002unclassified Harpoon Therapeutics, Inc… NCT04184050
Ph1 BL-M24D1unclassified Sichuan Baili Pharmaceuti… NCT07255898
Ph1 Belantamab mafodotin, Bortezomib, Lenalidomideunclassified GlaxoSmithKline NCT04091126
Ph1 Invivo CAR-Tunclassified Chongqing Precision Biote… NCT07239323
Ph1 3D189unclassified 3D Medicines NCT05320809
Ph1 Belantamab mafodotinunclassified GlaxoSmithKline NCT04398745
Ph1 Selinexor, Ruxolitinib, Methylprednisoloneunclassified Oncotherapeutics NCT06225310
Ph1 TQB2029 injectionunclassified Chia Tai Tianqing Pharmac… NCT06700395
Ph1 CBG002 CAR-T Cell Suspensionunclassified Carbiogene Therapeutics C… NCT06705725
Ph1 Autologous CAR-T cell therapy expressing the BAFF-ligand.unclassified Luminary Therapeutics NCT05546723
Ph1 OriCAR-017unclassified OriCell Therapeutics Co.,… NCT06271252
Ph1 Administration of CAR T-cells at 3 different dose levelsunclassified Kure Cells, INC NCT07611149
Ph1 HRS-3738unclassified Jiangsu HengRui Medicine … NCT05363800
Ph1 BP2202unclassified BrightPath Biotherapeutic… NCT07667868
Ph1 SHR-5421 for Injectionunclassified Suzhou Suncadia Biopharma… NCT07652281
Drugs in this landscape: Talquetamab · Teclistamab · Daratumumab · Linvoseltamab · Elranatamab · Lenalidomide · Belantamab mafodotin · Isatuximab · Isatuximab intravenous (IV)

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed
Johnson & Johnson 28 27 2
GSK 19 8 4
AbbVie 16 5 7
Regeneron 11 1 1
Bristol-Myers Squibb 9 55 17
Sanofi 8 12 1
Roche 8 12 1
Pfizer 8 10 2
Qilu Pharmaceutical Co., Ltd. 5 0 0
AstraZeneca 4 1 2
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 4 0 0
Nanjing IASO Biotechnology Co., Ltd. 4 0 0
Oncotherapeutics 3 5 5
Kite, A Gilead Company 3 0 2
Genrix (Shanghai) Biopharmaceutical Co., Ltd. 3 1 0

All 15 active Multiple Myeloma sponsors

Unlock the remaining 7 sponsors with active / completed / failed counts — sortable and exportable.

Unlock with Pro

How the field has grown

New-trial starts peaked in 2021 (120 registered); 2025 saw 106. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (137 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016
98
2017
110
2018
100
2019
117
2020
73
2021
120
2022
111
2023
106
2024
104
2025
106
2026
94

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (7)
170
2017 (14)
347
2018 (7)
462
2019 (14)
269
2020 (10)
302
2021 (9)
587
2022 (14)
832
2023 (12)
460
2024 (14)
431
2025 (18)
413
2026 (18)
400

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT03844048 ACTIVE NOT RECRUITING
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie n=165
NCT06615479 RECRUITING
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company n=440
NCT07095452 RECRUITING
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie n=660
NCT07579234 RECRUITING
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD n=261
NCT06182774 RECRUITING
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Canadian Cancer Trials Group n=570
NCT06152575 RECRUITING
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer n=492
NCT07518186 RECRUITING
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC n=700
NCT04181827 ACTIVE NOT RECRUITING
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
Janssen Research & Development, LLC n=419
NCT05083169 ACTIVE NOT RECRUITING
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC n=587
NCT04923893 ACTIVE NOT RECRUITING
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Janssen Research & Development, LLC n=743
NCT07222761 RECRUITING
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals n=915
NCT05438043 RECRUITING
A Study of Daratumumab
Janssen Research & Development, LLC n=500
NCT07258511 RECRUITING
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC n=400
NCT05552222 RECRUITING
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Janssen Research & Development, LLC n=1,590
NCT07569757 NOT YET RECRUITING
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=260
NCT06413498 RECRUITING
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Kite, A Gilead Company n=450
NCT04566328 RECRUITING
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
ECOG-ACRIN Cancer Research Group n=1,450
NCT03937635 RECRUITING
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
ECOG-ACRIN Cancer Research Group n=288
NCT05623020 RECRUITING
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Pfizer n=1,116
NCT05020236 RECRUITING
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Pfizer n=944
NCT03319667 ACTIVE NOT RECRUITING
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Sanofi n=475
NCT01169337 ACTIVE NOT RECRUITING
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
National Cancer Institute (NCI) n=226
NCT05519085 RECRUITING
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Celgene n=810
NCT07391657 RECRUITING
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
AstraZeneca n=508
NCT00602641 ACTIVE NOT RECRUITING
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI) n=306
NCT07555938 RECRUITING
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Hoffmann-La Roche n=380
NCT06868654 ACTIVE NOT RECRUITING
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
GlaxoSmithKline n=72
NCT06868667 ACTIVE NOT RECRUITING
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
GlaxoSmithKline n=24
NCT04246047 ACTIVE NOT RECRUITING
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
GlaxoSmithKline n=494
NCT03823534 RECRUITING
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
St. Louis University n=60
NCT06679101 RECRUITING
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
GlaxoSmithKline n=520
NCT05317416 ACTIVE NOT RECRUITING
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Pfizer n=854
NCT05455320 ACTIVE NOT RECRUITING
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
Janssen Research & Development, LLC n=864
NCT00644228 ACTIVE NOT RECRUITING
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
National Cancer Institute (NCI) n=525
NCT05572515 ACTIVE NOT RECRUITING
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC n=614
NCT03993912 ACTIVE NOT RECRUITING
Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
University Hospital, Lille n=294
NCT06980480 RECRUITING
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Takeda n=183
NCT04975997 ACTIVE NOT RECRUITING
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Celgene n=939
NCT06918002 RECRUITING
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Intergroupe Francophone du Myelome n=824
NCT05552976 ACTIVE NOT RECRUITING
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Bristol-Myers Squibb n=606
NCT04162210 ACTIVE NOT RECRUITING
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline n=325
NCT05243797 RECRUITING
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
European Myeloma Network B.V. n=1,594
NCT07452198 RECRUITING
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd. n=358
NCT06932562 RECRUITING
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
European Myeloma Network B.V. n=1,000
NCT05257083 ACTIVE NOT RECRUITING
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
Stichting European Myeloma Network n=759
NCT07393282 RECRUITING
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Regeneron Pharmaceuticals n=270
NCT06158841 RECRUITING
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie n=380
NCT05827016 RECRUITING
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Bristol-Myers Squibb n=1,216
NCT06208150 RECRUITING
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Janssen Research & Development, LLC n=795
NCT05730036 RECRUITING
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals n=410
NCT06045806 ACTIVE NOT RECRUITING
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Celgene n=79
NCT03729804 ACTIVE NOT RECRUITING
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
University of Chicago n=250
NCT02659293 ACTIVE NOT RECRUITING
Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
University of Chicago n=180
NCT07138209 RECRUITING
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd. n=228
NCT07440290 NOT YET RECRUITING
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Cancer Research UK n=30
NCT07413809 RECRUITING
Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
The Affiliated People's Hospital of Ningbo University n=92
NCT04751877 ACTIVE NOT RECRUITING
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
Poitiers University Hospital n=270
NCT03710603 ACTIVE NOT RECRUITING
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
Stichting European Myeloma Network n=709
NCT03617731 ACTIVE NOT RECRUITING
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
University of Heidelberg Medical Center n=662
NCT06216158 RECRUITING
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center n=411
NCT07297329 RECRUITING
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Sinocelltech Ltd. n=292
NCT01208662 ACTIVE NOT RECRUITING
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Paul Richardson, MD n=729
NCT03246529 ACTIVE NOT RECRUITING
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
BioLineRx, Ltd. n=180
NCT07319897 RECRUITING
68Ga-BCMA PET/CT in Multiple Myeloma
Peking University First Hospital n=300
NCT06514508 RECRUITING
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Guangzhou Gloria Biosciences Co., Ltd. n=60
NCT07285239 NOT YET RECRUITING
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
PrECOG, LLC. n=500
NCT04270409 ACTIVE NOT RECRUITING
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Sanofi n=337
NCT05028348 ACTIVE NOT RECRUITING
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
European Myeloma Network B.V. n=117
NCT05768178 RECRUITING
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Cancer Research UK n=30
NCT05405166 ACTIVE NOT RECRUITING
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
Sanofi n=531
NCT04459416 ACTIVE NOT RECRUITING
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
Memorial Sloan Kettering Cancer Center n=299
NCT07202052 RECRUITING
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Monash University n=900
NCT07202091 RECRUITING
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)
Monash University n=900
NCT07202078 RECRUITING
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
Monash University n=900
NCT07202065 RECRUITING
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
Monash University n=900
NCT05556720 ACTIVE NOT RECRUITING
Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial
Monash University n=960
NCT07181239 NOT YET RECRUITING
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
Keymed Biosciences Co.Ltd n=280
NCT04071457 ACTIVE NOT RECRUITING
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
SWOG Cancer Research Network n=1,100
NCT01863550 ACTIVE NOT RECRUITING
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
ECOG-ACRIN Cancer Research Group n=1,087
NCT06952478 RECRUITING
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Celltrion n=486
NCT06464991 RECRUITING
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Nanjing IASO Biotechnology Co., Ltd. n=240
NCT06580223 NOT YET RECRUITING
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology n=530
NCT00734877 ACTIVE NOT RECRUITING
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma
University of Arkansas n=382
NCT06508983 RECRUITING
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
Hangzhou Sumgen Biotech Co., Ltd. n=360
NCT03539744 ACTIVE NOT RECRUITING
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
AbbVie n=265
NCT06956170 ACTIVE NOT RECRUITING
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
GlaxoSmithKline n=21
NCT05561387 RECRUITING
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
SWOG Cancer Research Network n=510
NCT06895512 NOT YET RECRUITING
A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
Shanghai Henlius Biotech n=386
NCT04513639 RECRUITING
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Oslo University Hospital n=176
NCT04484623 ACTIVE NOT RECRUITING
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
GlaxoSmithKline n=302
NCT06879379 RECRUITING
KPD Consolidation After ASCT in NDMM Patients
Peking University People's Hospital n=202
NCT04483739 ACTIVE NOT RECRUITING
Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)
European Myeloma Network B.V. n=302
NCT04939142 ACTIVE NOT RECRUITING
A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Antengene Corporation n=150
NCT04096066 ACTIVE NOT RECRUITING
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
Fondazione EMN Italy Onlus n=84
NCT06742138 NOT YET RECRUITING
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
Qilu Pharmaceutical Co., Ltd. n=284
NCT06561854 RECRUITING
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
Assistance Publique - Hôpitaux de Paris n=318
NCT05665140 RECRUITING
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
University Hopsital Schleswig Holstein Campus Lübeck n=100
NCT03836014 ACTIVE NOT RECRUITING
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Assistance Publique - Hôpitaux de Paris n=436
NCT06588413 RECRUITING
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
Augusta University n=172
NCT04934475 ACTIVE NOT RECRUITING
MInimal Residual Disease Adapted Strategy
Intergroupe Francophone du Myelome n=791
NCT06187441 RECRUITING
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
Stichting Hemato-Oncologie voor Volwassenen Nederland n=599
NCT06520176 RECRUITING
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
The Affiliated People's Hospital of Ningbo University n=99
NCT06314698 NOT YET RECRUITING
Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease
RenJi Hospital n=478
NCT06296121 RECRUITING
A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma
Biocad n=252
NCT03948035 ACTIVE NOT RECRUITING
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Wuerzburg University Hospital n=576
NCT05558319 RECRUITING
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
PETHEMA Foundation n=480
NCT03742297 ACTIVE NOT RECRUITING
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years
PETHEMA Foundation n=462
NCT03562169 RECRUITING
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
University of Leeds n=406
NCT07624513 NOT YET RECRUITING
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute n=720
NCT07623798 NOT YET RECRUITING
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Innovent Biologics (Suzhou) Co. Ltd. n=255
NCT07649525 NOT YET RECRUITING
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
University of Leeds n=1,226
NCT07671287 NOT YET RECRUITING
GMMG-HD11/DSMM XXI/64007957MMY3010
University of Heidelberg Medical Center n=399
NCT07665450 NOT YET RECRUITING
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Janssen Research & Development, LLC n=1,000
NCT03891914 COMPLETED
Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma
University Hospital, Bordeaux n=20
NCT03901963 COMPLETED
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Janssen Research & Development, LLC n=200
NCT01231412 COMPLETED
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center n=174
NCT03301220 COMPLETED
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Janssen Research & Development, LLC n=390
NCT03652064 COMPLETED
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC n=395
NCT01191060 COMPLETED
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
University Hospital, Toulouse n=700
NCT07428369 WITHDRAWN
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Regeneron Pharmaceuticals
NCT05804032 COMPLETED
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center n=514
NCT03275285 COMPLETED
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
Sanofi n=302
NCT01208766 COMPLETED
Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Stichting Hemato-Oncologie voor Volwassenen Nederland n=1,503
NCT05675319 TERMINATED
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
Universitätsklinikum Hamburg-Eppendorf n=28
NCT03180736 COMPLETED
Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex
Stichting European Myeloma Network n=304
NCT02252172 COMPLETED
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC n=737
NCT01241708 COMPLETED
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Hackensack Meridian Health n=148
NCT02136134 COMPLETED
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC n=498
NCT02195479 COMPLETED
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC n=706
NCT05461209 WITHDRAWN
A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
Janssen Research & Development, LLC
NCT02066454 COMPLETED
Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs
University Hospital, Grenoble n=108
NCT03941860 COMPLETED
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
National Cancer Institute (NCI) n=1
NCT03158688 COMPLETED
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
Amgen n=466
NCT02076009 COMPLETED
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC n=569
NCT03277105 COMPLETED
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC n=522
NCT02541383 COMPLETED
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
Intergroupe Francophone du Myelome n=1,085
NCT03748953 COMPLETED
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
Millennium Pharmaceuticals, Inc. n=37
NCT03357952 COMPLETED
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC n=10
NCT01539083 COMPLETED
Velcade (Bortezomib) Consolidation After Transplant
Janssen Scientific Affairs, LLC n=256
NCT02990338 COMPLETED
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
Sanofi n=307
NCT02181413 COMPLETED
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
Takeda n=656
NCT01093196 COMPLETED
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Fondazione EMN Italy Onlus n=660
NCT01091831 COMPLETED
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
Fondazione EMN Italy Onlus n=389
NCT03595800 COMPLETED
Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen
Institut Paoli-Calmettes n=9
NCT03110562 COMPLETED
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Karyopharm Therapeutics Inc n=402
NCT03859427 COMPLETED
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Amgen n=454
NCT02215980 COMPLETED
STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS
Fondazione EMN Italy Onlus n=210
NCT03952091 COMPLETED
TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
TJ Biopharma Co., Ltd. n=289
NCT06232707 WITHDRAWN
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Celgene
NCT03234972 COMPLETED
A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC n=213
NCT03217812 COMPLETED
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Janssen Research & Development, LLC n=220
NCT03151811 TERMINATED
A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide
Oncopeptides AB n=495
NCT04549363 TERMINATED
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
GlaxoSmithKline n=16
NCT02312258 COMPLETED
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
Takeda n=706
NCT01951885 COMPLETED
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Case Comprehensive Cancer Center n=101
NCT02755597 COMPLETED
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
AbbVie n=291
NCT01850524 COMPLETED
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Millennium Pharmaceuticals, Inc. n=705
NCT04649060 TERMINATED
Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
Oncopeptides AB n=54
NCT01734928 COMPLETED
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Celgene n=559
NCT02516696 TERMINATED
BiRd vs. Rd as Initial Therapy in Multiple Myeloma
Weill Medical College of Cornell University n=12
NCT02726581 COMPLETED
An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
Bristol-Myers Squibb n=170
NCT01564537 COMPLETED
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Takeda n=722
NCT01090089 COMPLETED
Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH n=348
NCT03651128 COMPLETED
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Celgene n=386
NCT01568866 COMPLETED
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
Amgen n=929
NCT01345019 COMPLETED
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen n=1,718
NCT01335399 COMPLETED
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Bristol-Myers Squibb n=748
NCT02412878 COMPLETED
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
Amgen n=478
NCT01080391 COMPLETED
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
Amgen n=792
NCT01239797 COMPLETED
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb n=646
NCT03029234 COMPLETED
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
Amgen n=126
NCT02197221 COMPLETED
Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma
University Hospital, Toulouse n=300
NCT01712789 COMPLETED
Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Celgene n=682
NCT01109004 COMPLETED
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
National Heart, Lung, and Blood Institute (NHLBI) n=758
NCT02576977 TERMINATED
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
Merck Sharp & Dohme LLC n=251
NCT02495922 COMPLETED
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
University of Heidelberg Medical Center n=564
NCT02579863 TERMINATED
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Merck Sharp & Dohme LLC n=310
NCT04288765 WITHDRAWN
Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma
Grupo Cooperativo de Hemopatías Malignas
NCT01891643 TERMINATED
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
Bristol-Myers Squibb n=23
NCT00967343 TERMINATED
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Kiadis Pharma n=40
NCT00773747 COMPLETED
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Merck Sharp & Dohme LLC n=637
NCT02112175 COMPLETED
Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM
Celgene n=46
NCT03440411 TERMINATED
Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment
Fondazione EMN Italy Onlus n=9
NCT01102426 COMPLETED
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
PharmaMar n=255
NCT00750009 COMPLETED
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
Case Comprehensive Cancer Center n=583
NCT02322320 COMPLETED
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
National Heart, Lung, and Blood Institute (NHLBI) n=273
NCT01413178 COMPLETED
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
M.D. Anderson Cancer Center n=205
NCT01023308 COMPLETED
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Novartis Pharmaceuticals n=767
NCT01146834 COMPLETED
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
Weill Medical College of Cornell University n=47
NCT00928486 COMPLETED
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
Celgene n=25
NCT00689936 COMPLETED
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Celgene n=1,623
NCT01324947 COMPLETED
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Celgene n=74
NCT02811978 COMPLETED
Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma
Janssen Research & Development, LLC n=81
NCT01818752 COMPLETED
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
Amgen n=955
NCT02145598 TERMINATED
Treatment Optimization in Patients With Untreated Multiple Myeloma
Dr. med. Lars-Olof Muegge n=85
NCT01470131 TERMINATED
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
AB Science n=147
NCT00869206 COMPLETED
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Alliance for Clinical Trials in Oncology n=1,822
NCT01311687 COMPLETED
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
Celgene n=455
NCT01908621 COMPLETED
Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.
Maria Sklodowska-Curie National Research Institute of Oncology n=90
NCT02155634 WITHDRAWN
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
Celgene
NCT01002248 TERMINATED
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
AEterna Zentaris n=135
NCT00891384 COMPLETED
Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH n=194
NCT03402295 COMPLETED
Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation
Grupo de Estudos Multicentricos em Onco-Hematologia n=311
NCT02406144 COMPLETED
Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma
PETHEMA Foundation n=316
NCT00657553 TERMINATED
Preemptive Strike With Bortezomib in Multiple Myeloma Patients
University of Arkansas n=10
NCT02419118 COMPLETED
"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
Vejle Hospital n=4
NCT01916252 COMPLETED
Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old
PETHEMA Foundation n=460
NCT00516503 COMPLETED
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Alliance for Clinical Trials in Oncology n=208
NCT00714259 TERMINATED
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
University of Alabama at Birmingham n=5
NCT01302392 COMPLETED
A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
Amgen n=315
NCT00755040 COMPLETED
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Vanderbilt-Ingram Cancer Center n=164
NCT01910987 COMPLETED
Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib
Janssen-Cilag International NV n=80
NCT00719563 COMPLETED
American Ginseng in Treating Patients With Fatigue Caused by Cancer
Alliance for Clinical Trials in Oncology n=364
NCT00984828 TERMINATED
Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients
Shanghai Jiao Tong University School of Medicine n=23
NCT00861250 COMPLETED
Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT
Tampere University Hospital n=47
NCT00892346 SUSPENDED
Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma
Shanghai Jiao Tong University School of Medicine n=80
NCT01530594 COMPLETED
Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma
King Faisal Specialist Hospital & Research Center n=440
NCT01621672 COMPLETED
UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma
University of Arkansas n=42
NCT01971658 COMPLETED
Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)
Nantes University Hospital n=358
NCT00838357 COMPLETED
A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).
Genzyme, a Sanofi Company n=118
NCT01160380 COMPLETED
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
Oncotherapeutics n=50
NCT01309334 COMPLETED
Imaging Young Myeloma (IMAgerie JEune Myélome)
Nantes University Hospital n=152
NCT00813150 COMPLETED
Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma
Janssen-Cilag G.m.b.H n=96
NCT01301963 TERMINATED
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide
Case Comprehensive Cancer Center n=9
NCT00950911 COMPLETED
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
Amgen n=35
NCT01110824 COMPLETED
Prevention of Left Ventricular Dysfunction During Chemotherapy
Hospital Clinic of Barcelona n=90
NCT01266811 WITHDRAWN
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Centocor, Inc.
NCT00799461 COMPLETED
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium n=1,337
NCT00722566 COMPLETED
A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma
Millennium Pharmaceuticals, Inc. n=222
NCT00546780 COMPLETED
A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
Bristol-Myers Squibb n=31
NCT01016548 COMPLETED
Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy
University Health Network, Toronto n=42

Full Multiple Myeloma Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Frequently asked

Common questions about the Multiple Myeloma landscape

How many companies are developing Multiple Myeloma treatments?
13 companies have active or registered Multiple Myeloma programs in TheraRadar's competitive landscape (91 classified trials). The most active are Johnson & Johnson, Regeneron, and Bristol-Myers Squibb.
What mechanisms of action are being developed for Multiple Myeloma?
15 distinct mechanisms of action appear across the Multiple Myeloma pipeline, including CD3, T cell surface glycoprotein CD3, Anti-CD38 (mAb), BCMA, and BCMA × CD3 (bispecific).
What is the most crowded mechanism in Multiple Myeloma?
CD3 is the most contested mechanism in Multiple Myeloma, with 11 programs mapped to it.
Are there upcoming Multiple Myeloma clinical readouts or FDA decisions?
Near-term Multiple Myeloma catalysts include JNJ-68284528 (data readout, Aug '26); Daratumumab (FDA decision, Aug '26); Talquetamab (data readout, Aug '26). Dates combine estimated trial primary-completion readouts and confirmed FDA decision dates.
Where does TheraRadar's Multiple Myeloma landscape data come from?
Programs are derived from industry-sponsored ClinicalTrials.gov registrations (2008–present) and classified by mechanism of action using a curated rule set plus an LLM pipeline. Every cell links to its underlying trials, so each program is verifiable.
Is the Multiple Myeloma heatmap free to use?
Yes — viewing and searching the Multiple Myeloma heatmap is free. A TheraRadar Pro subscription adds advanced filters, row/column selection, and one-click export to PowerPoint, PDF, and CSV.
How this is built — methodology & limits

These grids are only as good as the data and the classification behind them — so here is exactly what goes in, what stays out, how every assignment is made, and where the limits are.

Where the data comes from

Every heatmap is built from the public ClinicalTrials.gov registry, via its official API — interventional drug and biologic trials with a start date of 2008 or later. The master index holds over 145,000 trials and is refreshed weekly (see the “updated” date on this page). A disease landscape draws only from the active, Phase 1–3, industry-sponsored slice of that index.

  • In scope: industry-sponsored trials in Phase 1, 2, or 3, with an active status (recruiting, active-not-recruiting, not-yet-recruiting, or enrolling by invitation). Phase 4 sits in the index but is left out of the landscapes.
  • Filtered out: deeply stale programs (a primary completion date more than two years past with no update to completed or terminated); basket trials and incidental mentions (a trial counts toward a disease only when that disease is genuinely the subject of study — not a secondary cohort, an organ-of-origin overlap, or a passing mention); and healthy-volunteer studies.

We do not exclude trials by sponsor geography. Where a sponsor is based in China, the program is flagged on the page rather than hidden, so you can weigh it yourself. An automated test fails the weekly refresh if the underlying index is more than 14 days old, so a published grid is never built on a stale index.

How a trial is matched to a disease

Matching uses a structured medical ontology, not keyword guessing, and is designed so that no trial is ever silently dropped — every trial that clears the filters gets a classification, even if that is just “Other.” It runs as an ordered sequence of steps, stopping at the first that applies:

  1. Healthy-volunteer studies are set aside as non-disease trials.
  2. Ontology match — each tracked disease is linked to its official identifiers in the standard medical taxonomy (MeSH), so a trial can be matched even when its text uses a synonym.
  3. Curated disease patterns — a hand-maintained library of over 150 disease-name patterns covers the more granular indications across oncology, hematology, infectious disease, cardiometabolic, immunology, and neuropsychiatry.
  4. Basket guard — a trial matching four or more distinct diseases, or carrying explicit basket language (“tumor-agnostic,” “all solid tumors,” “pan-cancer”), is grouped into a single advanced-solid-tumor category rather than over-counted across every cancer it touches.
  5. Therapeutic-area roll-up — a trial with no specific match, but which the taxonomy still places under a broad area, is assigned to that area (“Oncology — other,” “Immunology — other,” …), checking cancers first so a site-specific tumor isn’t filed under its anatomical system.

A “drop-if-parent-present” rule keeps a generic name from drowning out a subtype: a trial matching both lupus and lupus nephritis is reported only as lupus nephritis. Internal abbreviations are translated to the plain disease names used across the site (for example, “CRC” becomes “Colorectal Cancer”), and the same classifier is shared by every heatmap, so the same trial always maps to the same disease wherever it appears.

How a drug is matched to its mechanism

Mechanism of action is the hardest part to get right, so it is assigned in layers — leaning on curated and public data first, with AI as a last resort:

  1. Curated rulebook (first). A rulebook we maintain — over 600 drug-to-mechanism rules — is checked first, matching on drug names, trial acronyms, sponsor trial identifiers, and intervention lists. First match wins, which stops a combination trial from being counted several times.
  2. Public molecular-target data. Where no rule applies, each intervention’s target is looked up in a public target database, with verbose or gene-symbol labels normalized into consistent short forms so one target isn’t split across several columns.
  3. Standard-of-care backbones. A small set of rules recognizes common combination scaffolds (checkpoint-inhibitor monotherapy, standard chemotherapy regimens, established standard-of-care agents) so they aren’t mistaken for the experimental arm.
  4. AI as a last resort, then cross-checked. Only for genuinely opaque sponsor code-names that none of the first three steps can resolve do we ask an AI model to propose a mechanism — applied only above a fixed confidence bar, then automatically cross-checked against the sponsor’s own pipeline page. Where AI and the sponsor agree, the program is marked sponsor-verified. Where they contradict, the label is discarded entirely — not shown, not counted.

New mechanism rules are independently double-verified before they’re trusted — a second, adversarial pass set up to disprove the first — and each is checked so it can’t mislabel an unrelated trial. Drugs whose mechanism isn’t publicly disclosed are shown openly as “Emerging — not yet disclosed” rather than guessed at: for a tool meant to support real decisions, “we don’t yet know” is a more trustworthy answer than a confident guess.

Where AI is used — and where it isn’t

The disease and mechanism matching above is driven first by deterministic rules and public ontologies, not AI. AI plays three bounded, disclosed roles: (1) an optional extra check that a trial genuinely studies the disease, on top of the ontology match; (2) inferring a trial’s treatment setting on the competitive grids when the rules don’t cover it, only above a fixed confidence bar; and (3) the last-resort mechanism step above, always cross-checked against the sponsor’s disclosures. Wherever an AI label reaches a cell, the page marks it (⚙️ or ✅) — AI is never the silent, sole source of what you see.

What the on-page markers mean

  • ✅ Sponsor-verified — AI proposed the mechanism and it matched the sponsor’s own pipeline page. High-trust.
  • ⚙️ AI-classified — AI proposed it above the confidence bar but it has not yet been cross-checked against the sponsor. Useful; verify before citing. It never means a person reviewed it.
  • ⚡ First-in-class — the mechanism hasn’t appeared in any other disease landscape we’ve built. This reflects the scope of landscapes published so far (the tooltip lists exactly which were scanned), not an absolute claim about the whole market.
  • 🌱 First-in-indication — the only program competing on that mechanism within this disease.
  • 🆕 NME candidate — the interventions match no drug in our approved-drug index, suggesting a new molecular entity. The index is incomplete — a signal, not a regulatory fact.
  • 🔗 Combination · 👶 Pediatric · 🔥 Hot (readout within six months) · ⏳ Stale (completion date passed but still marked active — often a stalled program).

Sponsor names are resolved through a curated parent/subsidiary map; unrecognized sponsors appear under their raw registry name. The registry records the sponsor at a trial’s inception, so names are as originally filed and may not reflect later acquisitions. To keep large grids legible, mechanisms with a single program are listed separately rather than crowding the main grid, and very small players are listed below it — presentation choices only; nothing is removed from the underlying counts.

How we score programs — “what’s about to move”

Each program carries a 0–100 score that deliberately ranks imminence over raw stage — the most decision-relevant signal on a competitive grid. It is the sum of:

  • Clinical phase — up to 40 points (Phase 3 = 40, Phase 2 = 25, Phase 1 = 10).
  • Readout proximity — up to 60 points (next readout <6 months = 60, 6–12 months = 45, 1–2 years = 30, distant = 5).
  • Stale penalty — the score is halved if a trial is past its expected readout but still listed as active.

Cell colour on the grid is driven by this score, so a Phase 2 program about to read out can — correctly — outrank a dormant Phase 3 one. It answers “what’s about to move,” not just “what’s furthest along.”

What each grid plots

  • Indication landscape (this page) — one disease — companies (rows) × mechanism of action (columns): who is competing, and on what mechanism.
  • Company portfolio — one company — diseases (rows) × mechanism (columns): where it is active, and what it is betting on.
  • MOA platform — one mechanism family — drugs (rows) × diseases (columns): who is working on this class, and where.
  • Competitive landscape — one disease — mechanism (rows) × clinical setting (columns), aggregated across companies; setting columns are tailored per disease (e.g. lines of therapy in oncology; biologic-naïve vs. biologic-experienced in IBD).

What we don’t claim

  • First-in-class is editorial, not absolute — “not seen in the landscapes we’ve built,” not “novel across the industry.”
  • NME candidate is a signal, not a filing — absent from our (incomplete) approved-drug index.
  • Disease matching is automated and not exhaustively validated per disease — ontology and pattern matching can occasionally include or miss a trial.
  • AI-classified mechanisms are machine-proposed — unconfirmed unless they also carry ✅.
  • Sponsor names are as-filed and may lag current ownership.
  • Grids are as fresh as their last rebuild from the weekly index — no faster continuous refresh is claimed.

Data: ClinicalTrials.gov v2 API + FDA Drugs@FDA (approved-drug index). Spot an error? [email protected].

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only